Abzena

Effective drug development often hinges on reliable and precise bioassays and analytics. In the early phases, ensuring the accuracy of these analyses is crucial for promising candidates to progress through the pipeline. At Abzena, we address these challenges with our comprehensive suite of early-phase bioassays and analytical services. Our state-of-the-art technologies and expert team provide robust solutions to accurately characterize and quantify biomolecules, ensuring high standards of precision and reliability. Our services cover a range of critical activities, including assay development, validation, and routine sample analysis. By integrating innovative methodologies, we enhance the data quality that underpins key decision-making in drug development. Explore how our early-phase bioassays and analytics can streamline your project from discovery to clinical development. Access our latest info sheet to learn more: https://lnkd.in/ee6FDKsc #Bioassays #Analytics #CDMO #CRO #DrugDevelopment #Biotechnology #Abzena

Antibody-drug Conjugates (#ADCs) are redefining oncology therapeutics by offering targeted delivery of cytotoxic agents directly to cancer cells, thereby minimizing systemic toxicity. In a recent article in Drug Target Review, Abzena's Petra Dieterich, DPhil, MBA, Ian Glassford, PhD, MBA, and Jeffrey C. Mocny, Ph.D. discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors explore the need for further data to improve understanding and refine drug design with safety and efficacy in mind and the role that linker technologies and site-specific conjugation play in optimizing the therapeutic window of ADCs. Access the article to learn more about these promising therapeutics: https://lnkd.in/epRyCVnJ #CancerTreatment #Oncology #Biotechnology #TherapeuticAdvancements #CDMO #CRO

Access our recent case study with Sartorius focused on streamlining the conjugation of an Oligo-mAb program. From developing a robust process #development and #manufacturing strategy to utilizing membrane chromatography for endotoxin removal - see how we were able to expedite the conjugation process for this complex program. Click here to access the case study: https://lnkd.in/gFnkBD7p #CRO #CDMO #oligo #drugdevelopment #biopharmaceutical

Achieving your Target Product Profile (TPP) for your complex #biologic or #bioconjugate requires a robust and comprehensive approach to formulation development. Having delivered over 1400+ programs, our expert scientists prioritize solubility, delivery, safety, and sustained stability to ensure that your biopharmaceutical successfully transforms from a concept into a market-ready therapeutic.   Our flexible and customizable approach coupled with advanced technologies such as mass spectrometry, particle size assessment, and UPLC/HPLC systems, helps to ensure a streamlined and de-risked path to the clinic and beyond. From initial pre-formulation studies and generation of a formulation to support toxicology and first-in-human trials through to clinical in-use studies, formulation optimization, and device interaction studies - our comprehensive suite of services enables us to support your program throughout its entire lifecycle all under a single organization.   Access our latest info sheet to discover how our formulation development expertise can rapidly progress your project to its next target inflection point: https://lnkd.in/ef7JX5Hv   #FormulationDevelopment #CDMO #CRO #DrugDevelopment

Scaling-up a #biologic from clinical development to commercial production can present it's own set of unique challenges and possible time constraints. At Abzena, our comprehensive and fully integrated capabilities de-risks and streamlines the path to commercialization, enabling us tackle these challenges head-on.    Our cutting-edge facilities and expert teams support every stage - from process development and analytical method development through clinical manufacturing, tech transfer and onward to optimization and commercial manufacture. By offering high-quality, scalable manufacturing capabilities for monoclonal antibodies (mAbs), bispecifics (BsAbs), and other complex biologics, we ensure a robust and consistent manufacturing process that reduces risk, and speeds up time-to-market for your innovative therapies. Discover how Abzena can enhance and accelerate your manufacturing program today: https://lnkd.in/eHxGADyN #Biologics #Manufacturing #DrugDevelopment #CDMO

It's "Flashback Friday" featuring our San Diego facility tour event during #BIO last month. Guests were transported from the convention center to our state-of-the-art, clinical through commercial scale #biologics development and manufacturing facility in Sorrento Valley. Met with tasty beverages and appetizers, guests mingled with our #scientific and commercial leaders before heading on a tour of our process development and #analytical laboratories and #cGMP manufacturing suites. Thanks again to all who attended! If you're looking to scale-up your antibody program, come and take a tour and meet with our experts in San Diego today! For more information about our San Diego facilities, visit: https://lnkd.in/e9imbFnv #CDMO #CRO #DrugDevelopment #DrugSubstance

Independence Day is a time to honor the spirit of innovation and resilience that defines both our nation and industry. At #Abzena we are proud to contribute to the advancement of life-saving therapeutics and thankful for the freedom to push the boundaries of science and technology to improve global health. Thank you to our dedicated team, partners, and customers for their tireless work in bringing transformative therapies to patients worldwide. Let’s continue striving for a brighter, healthier future. #4thOfJuly #Innovation #LifeSciences #IndependenceDay #Biotech

At WADC in London our team presented a poster showcasing our unique ThioBridge™ conjugation technology that's been proven to improve the stability, potency and efficacy of antibody-drug conjugates (#ADCs).   ThioBridge™ addresses key challenges in ADC design and development by leveraging naturally occurring interchain disulfide bonds. This results in a more uniform drug-to-antibody ratio (DAR) profile, improved linker stability and precise site-specificity, ensuring no deconjugation or cross-conjugation issues.   Biopharma developers: How might this technology impact your ADC pipeline? Let's discuss the potential for improved efficacy and safety profiles today!   Access the poster here to learn more: https://lnkd.in/eU8p5ima

The development and application of technologies to engineer #antibodies and #proteins has rapidly grown over the last few decades, making engineering a critical aspect in the discovery, design and development of new therapeutic candidates. At Abzena, we eliminate the guesswork from protein engineering by offering robust solutions and proprietary approaches that can be tailored to your specific needs. Our expert team combines cutting edge in silico tools with decades of practical experience to design molecules that demonstrate optimal functionality and manufacturability.   Our unique and comprehensive design and engineering solutions include humanization, deimmunization, bispecifics, isotope switching, Fc Engineering, affinity maturation, developability and bioconjugation.   Access our latest info sheet to discover how our expert team, technologies and platforms can elevate your #biologic today! https://lnkd.in/eRZajbNE   #ProteinEngineering #CDMO #CRO #DrugDevelopment

In BioPharm International's latest issue, our VP of Cell Line Development (CLD), Simon Keen, shares innovative approaches that can optimize cell line development for next-generation biologics. From vector construction to rapid cloning strategies, he provides insights on how to build a flexible and efficient CLD platform that reduces the potential for bottlenecks in the development pathway.   "Efficient and flexible cell line development (CLD) platforms are critical to meeting the growing global demand for biologics." says Simon Keen.   Dive into the full article to explore these advancements in detail: https://lnkd.in/epHXRy3d #CDMO #CRO #Celllinedevelopment #DrugDevelopment